Hetero
-
{
- All
- News
- Videos
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Rs 550-Crore "Unaccounted" Income Found During Tax Raids On Hetero Pharma Group: Report
The Income Tax Department detected "unaccounted" income of Rs 550 crore and seized over Rs 142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources claimed on Saturday.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Rs 550-Crore "Unaccounted" Income Found During Tax Raids On Hetero Pharma Group: Report
The Income Tax Department detected "unaccounted" income of Rs 550 crore and seized over Rs 142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources claimed on Saturday.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
